^
    Back
    Association details:
    Biomarker:No biomarker
    Cancer:Burkitt Lymphoma
    Regimen:EPOCH-R (cyclophosphamide + doxorubicin hydrochloride + etoposide IV + + Rituxan (rituximab) + vincristine)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A2 - Guideline
    New
    Source:
    NCCN
    Excerpt:
    Burkitt lymphoma: suggested treatment regimens…second-line therapy…other recommended regimens…dose-adjusted EPOCH (etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin) + rituximab…regimen includes intrathecal methotrexate…
    Secondary therapy:
    methotrexate
    Evidence Level:
    Sensitive: A2 - Guideline
    New
    Source:
    NCCN
    Excerpt:
    Burkitt lymphoma: suggested treatment regimens…second-line therapy…other recommended regimens…dose-adjusted EPOCH (etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin) + rituximab…